Product data sheet



| MedKoo Cat#: 555160 | | 0 • |
|--|--|----------------|
| Name: SCH-336 | | // |
| CAS#: 447459-51-0 | | S _N |
| Chemical Formula: C ₂₃ H ₂₅ NO ₈ S ₃ | | O H |
| Exact Mass: 539.0742 | | S'. |
| Molecular Weight: 539.63 | | |
| Product supplied as: | Powder | j Š L L |
| Purity (by HPLC): | ≥ 98% | |
| Shipping conditions | Ambient temperature | |
| Storage conditions: | Powder: -20°C 3 years; 4°C 2 years. | |
| | In solvent: -80°C 3 months; -20°C 2 weeks. | 0 ~ |

1. Product description:

SCH-336 is a potent and selective human cannabinoid (hCB2) inverse agonist. SCH-336 is an inverse agonist at hCB2, as shown by its ability to decrease GTPgammaS binding to membranes containing hCB2, by the ability of GTPgammaS to left-shift SCH-336 binding to hCB2 in these membranes, and by the compound's ability to increase forskolin-stimulated cAMP levels in CHO cells expressing hCB2.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

| Solvent | Max Conc. mg/mL | Max Conc. mM |
|---------|-----------------|--------------|
| DMSO | 53.96 | 100 |

4. Stock solution preparation table:

| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg | | |
|---------------------------------------|---------|---------|----------|--|--|
| 1 mM | 1.85 mL | 9.27 mL | 18.53 mL | | |
| 5 mM | 0.37 mL | 1.85 mL | 3.71 mL | | |
| 10 mM | 0.19 mL | 0.93 mL | 1.85 mL | | |
| 50 mM | 0.04 mL | 0.19 mL | 0.37 mL | | |

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

To be determined

In vivo study

Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. doi: 10.1124/jpet.105.093500. Epub 2005 Oct 28. PMID: 16258021.

7. Bioactivity

Biological target:

SCH-336 is a selective CB2 receptor inverse agonist (Ki = 1.8 nM, EC50 = 2 nM). SCH-336 displays 100-fold selectivity for CB2 receptors over CB1. SCH-336 increases Forskolin stimulated cAMP accumulation in CHO cells expressing human CB2 receptors. SCH-336 inhibits leukocyte migration in a murine model of delayed-type hypersensitivity and inhibits antigen-induced lung eosinophilia in a mouse allergy model.

Product data sheet



In vitro activity

To be determined

In vivo activity

Selective CB2 inverse agonists, like SCH-336, may be promising for treating acute and chronic inflammatory disorders characterized by leukocyte recruitment. Oral administration of SCH-336 significantly inhibited leukocyte trafficking induced by chemokines or antigen challenge in rodent models. SCH-336 blocked ovalbumin-induced lung eosinophilia in a mouse model of allergic asthma.

Reference: J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. https://pubmed.ncbi.nlm.nih.gov/16258021/

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.